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Background: Although asthma morbidity can be prevented through long-term controller medication, most patients
with persistent asthma do not take their daily inhaled corticosteroid. The objective of this study was to gather patients’
insights into barriers and facilitators to taking long-term daily inhaled corticosteroids as basis for future knowledge
translation interventions.
Methods: We conducted a collective qualitative case study. We interviewed 24 adults, adolescents, or parents of
children, with asthma who had received a prescription of long-term inhaled corticosteroids in the previous year. The
one-hour face-to-face interviews revolved around patients’ perceptions of asthma, use of asthma medications, current
self-management, prior changes in self-management, as well as patient-physician relationship. We sought barriers and
facilitators to optimal asthma management. Interviews were transcribed verbatim and transcripts were analyzed using
a thematic approach.
Results: Patients were aged 2–76 years old and 58% were female. Nine patients were followed by an asthma specialist
(pulmonologist or allergist), 13 patients by family doctors or pediatricians, and two patients had no regular follow-up.
Barriers and facilitators to long-term daily inhaled corticosteroids were classified into the following loci of responsibility
and its corresponding domains: (1) patient (cognition; motivation, attitudes and preferences; practical implementation;
and parental support); (2) patient-physician interaction (communication and patient-physician relationship); and (3)
health care system (resources and services). Patients recognized that several barriers and facilitators fell within their
own responsibility. They also underlined the crucial impact (positive or negative) on their adherence of the quality of
patient-physician interaction and health care system accessibility.
Conclusions: We identified a close relationship between reported barriers and facilitators to adherence to long-term
daily controller medication for asthma within three loci of responsibility. As such, patients’ adherence must be
approached as a multi-level phenomenon; moreover, interventions targeting the patient, the patient-physician
interaction, and the health care system are recommended. The present study offers a potential taxonomy of
barriers and facilitators to adherence to long-term daily inhaled corticosteroids therapy that, once validated, may
be used for planning a knowledge translation intervention and may be applicable to other chronic conditions.
Keywords: Asthma, Patient perspective, Adherence, Long-term daily controller medication, Inhaled corticosteroids,
Barriers, Facilitators* Correspondence: francine.m.ducharme@umontreal.ca
1Clinical Research and Knowledge Transfer Unit on Childhood Asthma,
Research Centre, Sainte-Justine University Health Centre Montreal, Quebec,
Canada
7Department of Epidemiology, Biostatistics and Occupational Health, McGill
University, Montreal, Quebec, Canada
Full list of author information is available at the end of the article
© 2015 Peláez et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Peláez et al. BMC Pulmonary Medicine  (2015) 15:42 Page 2 of 11Background
Nearly 60% of patients with persistent asthma have sub-
optimal asthma control, a figure that has remained un-
changed since 2000 in Canada and abroad [1-3].
Suboptimal asthma control is associated with prevent-
able asthma symptoms, overuse of bronchodilators (i.e.,
rescue medication), functional impairment (e.g., work
absenteeism), increased health service use (e.g., emer-
gency visits), and even death [4,5]. The goal of asthma
management is to control the disease so that patients
may lead a normal active life and prevent long-term im-
pairment. [6,7]. Through guided self-management plans,
patients learn to manage their asthma under the recom-
mendations of their physician [6,8,9]. The cornerstone of
asthma management in individuals with persistent
asthma is the daily use of long-term controller medica-
tion for the disease, most notably, inhaled corticoste-
roids [3]. Unfortunately, adherence to recommended
medications remains very low and is recognized as the
main cause of therapeutic failure and preventable
asthma morbidity [10,11].
The lack of prior identification of relevant barriers and
facilitators before planning an intervention is one of the
main reasons why knowledge translation interventions
aiming at various clinical issues have either failed or had
a modest effect [12]. Whereas barriers to adherence to
long-term controller medication for asthma have been
extensively studied in the last decade, the literature on
facilitators of adherence to asthma controller medication
is scant.
Most commonly reported barriers to long-term con-
troller medication for asthma include: fear of adverse ef-
fects, addiction, or dependence to medication; belief that
the medication does not help or is not necessary; con-
cerns about a diminishing effectiveness of medication
over time; preference for alternative asthma manage-
ment; sense of only an intermittent need for medication;
inconvenient dosage regimens; inadequate knowledge of
the medication and/or the disease; cost of the medica-
tion; stigmatization of the affected individual; dislike of
the provider; medical comorbidity; and the lack of social
support [13-19]. In contrast, previously identified facili-
tators are: simple dosage regimens (e.g., one-daily dose);
patients’ knowledge related to the medication and the
disease; access to high-quality personalized health care;
coping with the disease; appropriate asthma self-
management; and, possessing a written action plan
[16,17,19-21]. A first taxonomy of facilitators of physi-
cians’ prescription behavior in the acute care setting,
which included 5 domains (knowledge, attitude, and be-
liefs; operationalization of guidelines; choice of medica-
tion; parent or patient-related factors; and setting-related
factors), was developed [22]. However, whether these fa-
cilitators would apply to patients’ behavior regardinglong-term medication intake, that is, over months and
years, in the non-acute setting is uncertain.
To our knowledge, no study has explored how patients
perceive the dynamic relationship between barriers to,
and potential facilitators of, daily medication adherence,
and no classification system of potential facilitators ex-
ists on which to survey specific groups of patients before
planning a knowledge translation intervention. The ob-
jective of the present study was to gain insight into fac-
tors perceived by patients as hindering or fostering their
daily adherence to inhaled corticosteroids, the preferred
medication to achieve asthma control. We also aimed to
develop a taxonomy of barriers and facilitators to sup-
port the development of knowledge translation interven-
tions to increase patients’ adherence to daily controller
medication for asthma over the long-term [23].
Methods
Design and procedures
We designed a collective qualitative case study [24]. A
similar study conducted in parallel, focusing on physi-
cians’ perspective, has been the object of a recent publi-
cation [25]. The study was approved by the Research
Ethics Board of the Sainte-Justine University Health
Centre; written informed consent from all participants
and parents, as well as written assent from children
aged 7 to 17 years, were obtained. In the informed con-
sents the participants both agreed to participate and ac-
knowledged that data would be used for research
dissemination.
The participants were recruited through advertising in
a free daily newspaper distributed in the greater Mon-
treal area and by word of mouth. Participants were se-
lected using criterion-based sampling [26] and were
eligible if they: (1) had (or were parents of a child with)
a confirmed diagnosis of asthma; (2) had visited a phys-
ician and renewed a prescription for inhaled corticoste-
roids in the past year, and (3) spoke and understood
English or French. Children under 12 years old were
interviewed with their parents. A financial compensation
of CAD $50 was given to each participant.
A one-hour face-to-face interview was conducted by
two experienced researchers (SP and AG) between June
and September 2011. The interview revolved around
patients’ perceptions of their asthma, use of asthma medi-
cations, current self-management, prior changes in self-
management, and patient-physician relationship. The
interview guide was developed in French and translated
into English. A copy of the English version is available in
Appendix A. Examples of the questions were: “Why do
you take (or not) the medication in the way you have just
described? What would you think/do if your doctor rec-
ommends that you take long-term controller medication
(i.e., inhaled corticosteroids)?” We adhered to the idea that
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the interviewer and the interviewee” [27]. Thus, although
we followed the interview guide, we remained open and
flexible to discuss participants’ ideas. When needed, we
used detail-oriented (e.g., When did that happen? Who
else was involved?) and clarification probes (e.g., What
exactly do you mean?) to foster patients’ description and
illustration of discussed topics [26]. The interview was
pilot-tested with a parent of a child with asthma.
Data analysis
All interviews were audio-recorded, transcribed verba-
tim, and reviewed by the interviewers for accuracy [28].
For confidentiality purposes, each transcript was identi-
fied with two letters and a unique number indicating the
order in which the patients were recruited.
We used thematic analysis [29] to analyze the data.
Thematic analysis includes six phases: familiarizing with
data (e.g., reading the data), generating initial codes (e.g.,
coding interesting features), searching for themes (e.g.,
collating codes into potential themes), reviewing themes
(e.g., checking codes represent the themes), defining and
naming themes (e.g., refining analysis), and producing
the report. The analysis was guided by previous de-
scribed barriers and facilitators, as well as the “multi-
level model of asthma disparities” [30]. We chose this
model because, although it was developed to explain the
mechanisms involved in observed disparities in asthma,
it integrates essential research evidence that helps to
understand treatment non-adherence.
We conducted data analysis in parallel to ongoing data
collection. The first author holistically read and coded
all interviews and the fourth author (AG) coded 17
(71%) interviews. Double-coded interviews were com-
pared and disagreements were discussed until consensus
was achieved. A preliminary coding scheme was devel-
oped and discussed with two other team researchers
(AJM and FMD). Once the coding scheme achieved
consistency, it was discussed with the whole research
team to substantiate the interpretation of results.
We used the computer software MAXQDA (VERBI
GmbH, Germany, version 10) to support data analysis.
To better represent patients’ words, we selected quotes
from interviews recognizing that, when necessary, some
of these quotes were edited with regard to grammar and
syntax to enhance the clarity [28]. Back translation was




We interviewed 24 individuals: 16 adults with asthma
with a median (range) age of 44 (18 to 76) years, two ad-
olescents with asthma aged 15 and 18 years, and sixparents of children with asthma with a median (range)
age of 8.5 (2 to 12) years, 59% of participants were fe-
male. Five of the six children were 9 to 12 years old;
therefore, they were interviewed along with their par-
ents. Nine patients were followed by an asthma specialist
(pulmonologist or allergist), 14 patients by family doc-
tors or pediatricians, and one patient had no regular
follow-up. Additional patient information is presented in
Table 1. As case studies aim at achieving understanding
of a phenomenon, we exceeded our initial target of 20
patients to maximize redundancy in patients’ reported
barriers in this wide age spectrum.
Inspired by the “Multi-level model of asthma dispar-
ities” [30] we classified reported themes [i.e., barriers
and when available, matching facilitators] into three
loci of responsibility, namely: patient, patient-physician
interaction, and health care system. Themes were in
turn sub-classified into a total of seven domains (i.e.,
cognition; motivation, attitude, and preference; prac-
tical implementation; parental support; communication;
patient-physician relationship; and resources and ser-
vices). A comprehensive list of barriers, facilitators, and
exemplifying excerpts is available in Additional file 1:
Table S1.
Patient-related locus
We included in this locus psycho-social barriers and fa-
cilitators to adherence, that is, those related to the pa-
tients’ personal development, behavior, and interaction
with the family. Barriers and facilitators were further
grouped into four domains: cognition; motivation, atti-
tude, and preference; practical implementation; and par-
ental support.
Cognition
We classified within this domain barriers and matching
facilitators related to patients’ beliefs, perceptions, fears,
and knowledge. The belief that their asthma is not ser-
ious was reported by patients who refrained from taking
their medication because they disregarded the import-
ance of their symptoms and often did not recognize
asthma as a chronic condition that needed to be con-
trolled to prevent short-term events and long-term seque-
lae. Fears of addiction or dependence to their medication
were raised by patients who expressed concerns of be-
coming dependent on medication. Similarly, some patients
mentioned the belief of decreasing effectiveness of the
medication over time, as they assumed that daily use of
medication would lead to a need for increased dosage in
the future. None of these three barriers were matched by
any facilitator.
The perception that medication should be used in re-
sponse to symptoms, and not on a regular basis, trans-
lated in patients’ intake of medication solely when
Table 1 Patients’ characteristics
Patient
identification
Participant Sex Age category Category of asthma
duration (in years)
Followed by Owns a written
action plan
Physician specialty Workplace milieu
1 Patient Female 20-30 20-24 Allergist Non academic No
2 Patient Female 60-67 40-44 Pulmonologist Academic No
3 Parent + Patient Male 6-12 Not reported Pediatrician Academic Yes
4 Patient Male 60-70 1-4 Family physician Non academic No
5 Parent + Patient Male 6-12 5-9 Pediatrician Academic Yes
6 Patient Male 13-18 Not reported Family physician Non academic No
7 Patient Female 13-18 < 1 year Emergency physicians Academic No
8 Patient Male 40-50 5-9 Pulmonologist Non academic No
9 Patient Female 30-40 35-39 Pulmonologist Non academic No
10 Patient Female 20-30 15-19 Family physician Non academic No
11 Patient Female 50-60 10-14 Family physician Non academic No
12 Patient Female 30-40 30-34 Family physician Non academic Yes
13 Parent + Patient Male 6-12 5-9 Pediatrician Non academic No
14 Parent + Patient Male 6-12 5-9 Pediatrician Non academic Not reported
15 Parent + Patient Male 0-5 < 1 year Family physician Academic No
16 Patient Female 60-70 20-24 Pulmonologist Academic Yes
17 Patient Female 70-80 1-4 Pulmonologist Non academic No
18 Patient Male 30-40 1-4 Family physician Non academic No
19 Patient Female 40-50 5-9 Pulmonologist Academic Yes
20 Parent + Patient Male 6-12 1-4 Pediatrician Academic No
21 Patient Female 70-80 20-24 Pulmonologist Non academic No
22 Patient Female 20-30 20-24 Pulmonologist Non academic No
23 Patient Female 20-30 25-29 Family physician Non academic No
24 Patient Female 30-40 5-9 Family physician Non academic No
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symptoms abated. In contrast, the perception that self-
management should be used in anticipation of triggers
was a facilitator reported by patients who understood
the disease as a chronic condition, accepted the need for
long-term use of medication, and knew how to increase
dosage of medications in anticipation of potential triggers
that could result in an asthma flare-up/exacerbation.
Another barrier was inadequate or limited knowledge
about their medication, reported by patients who were
unsure about whether: they were taking the right medi-
cation, they were using the appropriate technique and
dose, and/or the medication they were taking was com-
patible with medications taken for other conditions. In
contrast, patients who reported being knowledgeable
about their medication with regards to how to take it,
how it worked, and what could be expected from its use,
described this knowledge as a key facilitator to adhering
to prescribed medications.
Patients also brought up two cognition-related barriers
that were matched by the same facilitator. The fear ofadverse effects of medication associated with use of an
inhaled corticosteroid alone or in combination with a
long-acting ß2-agonist and the belief that the medication
is not helpful or necessary, justified from the patients’
perspective why they had stopped taking the asthma
controller medication. A facilitator that counteracted
these two barriers was the perception of beneficial effects
of medication, which was often perceived as more im-
portant than their worries about the side effects of the
asthma controller medication.
Motivation, attitude, and preferences
We grouped, within this domain, four barriers and two
facilitators. Forgetfulness about taking their medication
was overcome by having established routines for taking
their medication.
Patients suffering from a lack of motivation explained
that it eroded over time, in part, because asthma was a
chronic disease and they had to deal with it throughout
their lives. Conversely, having a proactive attitude was a
facilitator to adhering to long-term controller medication
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tion and resources needed to adequately deal with the
disease.
Other barriers included a preference for a non-
pharmacological approach discussed by patients who
had a certain reticence towards taking traditional medi-
cations and reported developing parallel strategies to
avoid taking medication, such as cleaning the nasal air-
ways to improve breathing or relaxing in the presence of
a flare-up. Some patients expressed a preference for
restriction of daily physical activity instead of taking
medication, preferring to avoid physical effort to avoid
symptoms and thus decreasing the perceived need for
asthma controller medication.
Practical implementation
We classified within this domain themes related to the
actual intake of medication. The inconveniences of medi-
cation use revolved around different features of the
medication that the patients did not like (such as having
to take the medication more than once a day), described
as uncomfortable (e.g., the use of chambers), or that
demanded additional actions (e.g., having to brush their
teeth after its use). A facilitator was the perception of
medication as being patient-friendly because of easiness
and rapidity of medication intake.
Patients who brought up the cost of medication also
discussed the existence of the Quebec public drug plan
they benefited from, as a facilitator to adherence to
long-term medication intake. They explained that, with-
out this public drug plan that pays a substantial propor-
tion of the cost of their medication, they would probably
not be able to regularly take their medication.
Another facilitator patients discussed was having a
written action plan. Patients explained that having a plan
to monitor their symptoms and react in case of emer-
gency reassured them. Also, some of the patients who
did not receive a written action plan from their phys-
ician expressed positive opinions towards it and the
intention of using it if they were given one.
Parental support
Themes classified within this domain were solely
brought up by patients’ parents and revolved around the
collaboration among parents, as well as, the role of par-
ental perception of the child’s disease. The disagreements
between parents about their child’s disease led parents to
approach their child’s treatment differently, a case that
was more common in divorced parents. Instead, agree-
ment and partnership between parents, was a facilitator
beneficial for the child’s intake of daily controller
treatment.
A second barrier was the third-party perspective, per-
taining to the complexity of understanding the diseasefrom a non-personal stance. The difficulty in under-
standing and interpreting a child’s symptomatology led
parents to be unsure of the significance of the discom-
fort reported by their child. The gap in agreement on
the interpretation of symptoms in the presence of
asthma triggers between a child and his or her parents,
usually led parents to delay therapy and observe the
child for a certain period before administrating the
needed rescue medication.
Patient-physician interaction locus
We included, in this locus, themes pertaining to the
communication between the patient and the physician.
We classified barriers and facilitators into two domains:
communication and patient-physician relationship.
Communication
The themes classified within this domain referred to the
exchange of information between the patient and his or
her physician. Language limitations referred to the fact
that some instructions related to the disease and its
management, including medication (e.g., dose, regimen),
were given by physicians in a language (French or English)
in which patients were not fluent. The lack of a clear un-
derstanding led patients to be reluctant to take the pre-
scribed medication.
Medication adherence was also hindered by three
communication barriers directly related to the diagnosis
of asthma. The misbelief or lack of a clear diagnosis was
reported by patients who, misguided by doubts concern-
ing their diagnosis, refused to take long-term controller
medication. According to them, a clear diagnosis of the
disease resolved this barrier because once they were in-
formed of their condition they could proceed accord-
ingly. Other patients reported that their physicians had
diagnosed them with asthma, but due to a lack of formal
or objective assessment of disease severity (e.g., a respira-
tory function test), the severity of the disease remained
unclear to them. Receiving a formal or objective assess-
ment of disease severity was a clear facilitator; patients
who took repeated lung function tests over time ex-
plained that they could more easily ascertain the impact
of medication on their response to therapy. A third bar-
rier was the insufficient explanation of the condition and
its management in which patients hesitated to take
medication when instructions on how to manage the
disease were deficient. Conversely, sufficient explanation
of the condition and its management improved reported
adherence to asthma controller medication because
patients felt knowledgeable enough to manage their
asthma.
Disagreement concerning the prescription and the man-
agement plan was reported by patients who acknowledged
that they needed to take long-term controller medication,
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scribed dose, or the frequency, or the modality (e.g., in-
halers vs. pills). Patients’ concerns and hesitations were
dissipated when an agreement on the prescription and the
management plan was reached as a result of negotiation
with their physicians. Adapting the information provided
to the patients’ needs was also a key facilitator. Patients re-
ported the need for all explanations to be in lay language
to accept the disease and to have a better understanding
of the role of medications.
Patient-physician relationship
A poor patient-physician relationship led patients to be
less prone to taking the medication either because they
did not like the physician’s attitude during the medical
visit or felt that the prescribing physician was not suffi-
ciently aware of their clinical history to make an opti-
mal treatment decision. The latter was reported
particularly by patients who, at a given point in time,
had been followed by physicians working in an emer-
gency department or at a walk-in clinic. Conversely, a
good patient-physician relationship, where physicians
expressed empathy towards the patients’ needs and
took sufficient time to provide in-depth explanations
and discuss concerns, encouraged patients to adhere to
medication, even among those who were more reticent.
A second barrier was the lack of a patient-centered ap-
proach. Some patients felt that their physicians centered
the asthma management strategy solely on prescribed
medications, did not demonstrate empathy towards the
patients’ situation, and/or appeared driven by the desire
to minimize the visit duration. Conversely, a patient-
centered approach, in which the physician and the patient
shared a space to discuss the treatment, was reported as a
key facilitator to long-term controller medication adher-
ence because shared decision-making fostered the pa-
tients’ commitment towards therapy.
Health care system locus
Within this locus we classified barriers and facilitators
related to the navigation of the health system. Only one
domain, namely resources and services, was identified.
Four barriers and four facilitators fell within this do-
main. Some patients referred to a resistance to the
medical context and explained that sometimes, and for
different reasons, they were reluctant to consult the
medical system. These patients were less prone to follow
medical recommendations.
The lack of, or limited, health care resources such as
overloaded physicians, limited personnel, lack of special-
ists treating asthma, and long waiting lists, resulted in
patients not getting adequate guidance and treatment in
a timely fashion. In turn, access to health care profes-
sionals, asthma education, and prescription renewalnotably facilitated adherence to long-term controller
medication for asthma because being supervised and
getting clear information through asthma clinics for ex-
ample, made them feel reassured.
Some patients commented on the lack of a structured
follow-up plan. This issue was brought up by patients
who, in the past, did not have a formal follow-up. These
patients were reticent to take a medication that could be
associated with side effects, for an undetermined period
of time, and without having medical supervision of the
evolution of their disease. Conversely, a structured
follow-up by trained health care professionals enhanced
the patients’ intention to adhere to long-term controller
medication intake because patients were reassured.
The lack of, or poor, inter-professional communication
highlighted discordant or contradictory messages pro-
vided by different health care professionals that confused
patients and lead them to proceeding as per their own
inclinations, generally, against adhering to long-term con-
troller medication for asthma. Good inter-professional
communication was listed as a critical facilitator to ensure
patients’ understanding and acceptation of both the
disease and the treatment; and adherence to medica-
tion. Finally, some patients discussed one facilitator to
medication adherence within this domain that matched
no barriers: improved treatments. This facilitator was
referred by patients who have lived with asthma for many
years and explained that they found current treatments to
be more effective that previous ones, which gave them an
additional incentive to adhere to medication.
Discussion
As our objective was to gain insight into factors per-
ceived by patients as hindering or fostering their daily
adherence to asthma medication and to develop a tax-
onomy of barriers and facilitators to support the devel-
opment of interventions to increase patients’ adherence
to daily long-term controller medication for asthma, we
conducted face-to-face qualitative interviews with pa-
tients and parents of children with asthma. Among the
barriers and facilitators that emerged in the analysis, some
confirmed previous literature, others were rephrased to
better depict participants’ voices as well as some under-
represented and unique findings. Based on an adapted
version of the “multi-level model of asthma disparities,”
[30] we organized barriers and facilitators according to
three loci of responsibility, each with its correspondent
domains, namely: (1) patient (cognition; motivation, at-
titudes and preferences; implementation; and parental
support); (2) patient-physician interaction (communica-
tion and patient-physician relationship); and (3) health
care system (resources and services). We proposed a
taxonomy to support the development of knowledge
translation interventions to increase patients’ adherence
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pants’ perspectives offered an interesting view of the
interplay between facilitators and barriers related to pa-
tients’ reported behavior and intention regarding the
long-term intake of prescribed inhaled corticosteroids,
the cornerstone of asthma therapy.
Prioritizing the participants’ viewpoints allowed us to
confirm and further enrich previously identified barriers
to long-term controller medication for asthma [13-18]
namely: distorted beliefs associated with the disease and
the role, effectiveness and safety of medications; forgetful-
ness; lack of motivation; disagreement between parents
concerning their child’s disease; poor patient-physician re-
lationship; and issues related to health services and re-
sources. Also, our findings led us to reformulate some
barriers by closely reflecting the participants’ views. For
example, we referred to patients’ “poor patient-physician
relationship” rather than the more encompassing “dislike
of the provider” [13] because these patients stressed the
characteristics of the relationship, rather than an overall
and imprecise dislike of the provider. We also identified
new barriers pertaining to the patient locus (e.g., prefer-
ence for restriction of daily activity instead of taking medi-
cation); at the patient-physician interaction locus (e.g.,
disagreement concerning the prescription and the man-
agement plan); and at the health care system locus (e.g.,
resistance to the medical context).
Our interest to identify patient-perceived facilitators to
adhering to long-term controller medication for asthma
underlied the fact that although it is important to under-
stand patients’ perceived facilitators when developing
knowledge translation interventions, this topic has been
scarcely researched and reviewed. We confirmed several
facilitators to long-term controller medication for asthma
described in previous literature, such as having a written
action plan and patients’ knowledge related to the medica-
tion and the disease [19,21]. In addition, we identified new
items that serve to specify and enrich facilitators already
discussed in previous research. For example, according to
asthma educators interviewed by Chong and colleagues,
[19] a child’s initial diagnosis of asthma may cause paren-
tal stress; however, over time, most parents gain confi-
dence and appeared to cope with their child’s asthma
fairly well. Based on our findings, we may speculate that
the level of agreement and partnership between parents
with regards to their child’s diagnosis and treatment, likely
to evolve over the time, may contribute to modify parental
confidence in dealing with their child’s disease.
We also identified certain facilitators that may enhance
the translation of intention into sustained behavior, such
as perceiving the beneficial effects of medication, having
established routines for taking medication, and having a
proactive attitude. Similarly, adapting the feedback to
the patients’ need and involving the patient in the choiceof medication and frequency of daily use, two facilitators
identified in this study, represent specific instances of
considering the patients’ preference and convenience
when elaborating a treatment plan [17,19] Of note, the
perception of medication as being patient-friendly, the
availability of a public drug plan, and improved treat-
ments were facilitators discussed by these patients, but
not described in previous research. Notably, several facil-
itators were related to the interaction between patients
and physicians such as agreement with the prescription
and the management plan; a high-quality patient-
physician relationship; and a patient-centered approach
during the medical visit. These observations are consist-
ent with prior reports identifying trust and good bi-
directional communication as core constituents of a
patient-physician relationship [32,33]. Our proposed tax-
onomy of facilitators, derived from patients’ report of
adherence to long-term controller medication, is differ-
ent from, and more exhaustive than our prior taxonomy
of facilitators of physicians’ adherence to asthma guide-
lines in the emergency department; [22] yet, similar loci
of responsibility were identified: physician, patient, and
health care setting.
The proposed multi-level taxonomy carries two main
implications concerning potential interventions. First,
most facilitators were naturally paired with correspond-
ing barriers, within a specific locus and domain. For in-
stance, some barriers falling under the responsibility of
the patient, such as forgetfulness, could be easily over-
come by patients who established specific routines to
take medication. Similarly, disagreements between par-
ents about their child’s disease that lead to conflicts
concerning the administration of medication, may be
overcome by parental discussions leading to agreement
and partnership concerning their child’s diagnosis and
treatment. Second, although the proposed classification
serves to guide the loci of responsibility, some barriers
may be overcome by facilitators pertaining to a differ-
ent locus or domain. For example, the belief that
asthma is not serious, a cognition-related barrier classi-
fied within the patient locus, may be associated with
the misbelief or lack of a clear diagnosis or a mis-
communication at the patient-physician interaction
locus and/or the lack of a structured medical follow-up
attributed in part to the health care system. According
to these findings, the quality of the patient-physician
interaction, including negotiation concerning treatment
goals and management plans, may be an effective way
to address the multiple patient-related obstacles to ad-
herence. Finally facilitators pertaining the health care
system locus, such as the provision of drug insurance,
free/low cost asthma education, and timely access to
physicians, may have a positive impact on both the
patient- and the patient-physician interaction loci.
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are supported by promising or successful patient-related
interventions. For example, having experienced benefi-
cial effects of the medication may be used as a probe in
interventions using motivational interviewing or com-
munication approaches, which consists of helping pa-
tients to identify their ambivalence concerning a given
behavior [34]. Although there is preliminary evidence for
a positive effect of motivational interviewing on medica-
tion adherence, [35] these results have to be considered
cautiously due to small sample sizes and the pilot nature
of some studies [36]. Patient-centered approaches or in-
terventions, adapted to the specific needs and character-
istics of patients, have been shown to be effective to
address patient-related barriers and change patient be-
havior [37,38]. Furthermore, the rationale for a standard-
ized ‘Educating the educators approach,’ endorsed by the
Quebec Network for asthma education, the Canadian
Network for Asthma Care, and other organizations to
ensure the consistency of messages across health care
asthma educators and providers, relies on the concord-
ance of messages across professionals, a facilitator dis-
cussed by our patients [39]. We may speculate therefore
that the success of a written self-management plan in-
corporated in a prescription, shown to improve medication
adherence, probably facilitates a better communication
between physicians, pharmacists, and patients, [21,40] a
facilitator highlighted by patients.
In addition to the points discussed above, several
patient-related barriers could be favorably influenced by
the quality of the patient-physician interaction (e.g.,
patient-centered approach), strategies aiming at empower-
ing patients’ self-management (e.g., medication reminders)
or access to specific health care resources (e.g., asthma
education, lung function testing); consequently, the ap-
proach to behavioral change should be guided by a com-
prehensive multi-level perspective [37,41-43].
With regards to generalizability, we recognize that sev-
eral barriers identified in the previous literature were
not mentioned by patients in our study, such as interfer-
ence of life hassles, lack of social support, high levels of
anxiety, and reliance on the belief of God [13,15,44].
While we cannot rule out the possibility that we did
not achieve saturation, these barriers were possibly not
reported due to the socio-cultural and contextual char-
acteristics of our specific population. For example,
stigmatization may indeed be of low concern to our pa-
tients. Similarly, few previously identified facilitators,
such as parents’ positive view of asthma, [45] were not
brought up by our patients. Also, although proven ef-
fective to improve adherence, [21] only five of our 24
patients reported having a written self-management
plan. In addition, some barriers and facilitators identi-
fied in this study have been previously reported andwould therefore appear to apply to different settings,
we must acknowledge that their relative importance
may be influenced by the local culture and health care
system. Thus, we encourage researchers and health-
care decision makers to identify key facilitators in their
target population before implementing or testing a
knowledge translation intervention.
This study has several strengths and limitations. We
used a case study because this research strategy is an ef-
fective methodological research approach that results in
a comprehensive and integrated knowledge [46-48]. The
interview was flexible and allowed us to collect the ne-
cessary information to achieve our objective, respecting
and following the participants’ logics. As some character-
istics of asthma care (e.g., first vs. renewed prescription of
long-term inhaled corticosteroids) and participants (e.g.,
asthma severity and control, delay since diagnosis of
asthma, adherence to medication) were not documented,
the relationship between barriers, facilitators, asthma con-
trol, and medication adherence could not be explored.
With 18 patients over broad age spectrum and six parents
interviewed, we identified one specific difference in the
type of barriers and facilitators endorsed; this domain was
named ‘parental support’ referring to issues only parents
of children with asthma mentioned, such as disagreements
between parents about their child’s disease’ and ‘third-
party perspective.’ The diversity of participants’ age, roles
(i.e., adult and adolescent patients, parents and children),
health care provider specialty, and medical context
brought a wide spectrum of perspectives that we specific-
ally sought.
We did not designed the study to firmly identify differ-
ences in the endorsement of barriers and facilitators as-
sociated with specific patient characteristics (e.g., sex
and role) and specific outcomes (e.g., asthma control or
medication adherence); however, the proposed taxonomy
will support future studies exploring endorsement varia-
tions across patients. While qualitative research does not
aim at generalization, the consistency of reported bar-
riers and facilitators that matched those identified in
previous literature, emphasizes the validity of our find-
ings. The close match between barriers and facilitators
underlines the robustness of the proposed classification
by domains and loci of responsibility. As our study was
conducted in a setting with universal health care and
subsidized drug plans, certain barriers or facilitators
may not have been reported, thus affecting the
generalizability of our findings to other health care con-
texts. We did not specifically record patients’ self-report
of adherence or objectively documented adherence to
long-term controller medication for asthma. Although fa-
cilitators identified in this study genuinely arise from dis-
cussions held with patients, there is usually a gap between
intention and behavior, [49] such that the implementation
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havioral changes. Yet, several reported facilitators have
been previously shown effective in improving adherence.
Nevertheless, future research should both explore the
value of untested facilitators using objective documenta-
tion of medication intake and validate the taxonomy we
have developed.
The present study complements a similar parallel re-
search endeavor seeking the perspective of physicians re-
garding barriers and facilitators to prescribing long-term
controller medication for asthma [25]. Of interest, a large
proportion of facilitators voiced by physicians were also
identified by our participants, including patients’ attitude,
physician communication skills, inter-professional man-
agement approach, and patients’ education concerning the
disease and the medication, thus lending further support
to the validity and applicability of our findings.
Conclusions
While patients’ behavior falls within their own responsi-
bility, the quality of interaction with the physician (e.g.,
shared decision making) and access to key health care
resources (eg., lung function testing) and services (e.g.,
drug insurance) appear to play crucial roles in enhancing
or impeding patients’ adherence to long-term use of in-
haled corticosteroids, and importantly, to modify pa-
tients’ cognition, motivation, attitudes, and behaviors.
Consequently, patients’ adherence to a treatment plan
should be approached as a multi-faceted phenomenon.
Anchored in previous research, we offer an enriched
classification of barriers and facilitators to adherence to
therapy, issued from the concordance between both con-
cepts, that may enable the identification of population-
specific solutions to improve adherence that could be
formally evaluated subsequently. Although it deserves
validation, the proposed taxonomy may be applicable to
other populations and chronic conditions to plan inter-
vention studies.
Appendix A. Interview guide
The goal of the present interview is to know more about
your vision of asthma. We want to better understand,
from for your perspective, what are the challenges related
to the treatment, and especially to the self-management
of asthma. We also want to explore the possible facilita-
tors to face those challenges.
A. Introduction/Ice breaker
A.1. How did you learned that you (or your child) was
asthmatic?
(Explore whether the patient has been evaluated by his
or her physician/s or whether he or she has just received a
medication prescription without being formally diagnosed)A.2. Who follows your asthma? How did the/your
physician/s and/or healthcare professionals describe
asthma to you?
A.3. According to you, what are the objectives to be
attained during the treatment of asthma?
(If it was not discussed by the patient, explore whether
his or her asthma is considered mild or severe and what
were the elements that supported the diagnosis)
B. Medication intake
B.1. What type of medication/s are you taking for your
asthma? How do you take it? Do you follow the recom-
mendations prescribed by your physician? What do you
think of this medication?
(If not mentioned by the patient, explore the use of a
long-term controller medication and the meaning of
“long-term”)
B.2. Why do you take (or not) the medication in the
way you have just described?
(Explore different possible sources of influence, and among
them, which one was the most important for the patient).
B.3. (If needed, and adjusted depending on the patients’
responses to B.1. and B.2.)
What would you think/do if your doctor recommends
to you to take long-term controller medication (i.e., in-
haled steroids/corticosteroids)? (Explore the perception
of advantages and disadvantages associated to this type
of prescription and if relevant, see what could help or
prompt them to take it).
C. Consideration of medical recommendations
C.1. What do you do when your asthma worsens?
C.2. Why do you react this way when your symptoms
worsen?
(Explore different sources of influence, and if there are
many, see which one was the most important)
C.3. What helps you the most to manage periods of
asthma aggravation? What hinders or
makes it more difficult?
C.4. (If relevant and adjusted depending on the
participant’s responses to C.1., C.2., and C.3.)
What would you think/do if your physician recommends
you to follow a written action plan to manage your asthma?
(Explore the advantages and disadvantages of this type
of prescription practice, and if relevant, see what could
help or prompt them to follow a written action plan)
Peláez et al. BMC Pulmonary Medicine  (2015) 15:42 Page 10 of 11D. Patient-physician relationship
D.1. How would you describe your meetings with the
physician/s and health care professionals that treat/s
your asthma?
D.2. In your opinion, what is your role in the treat-
ment of asthma? What is the physician’s role?
And what is the health care professionals’ role?
Additional file
Additional file 1: Table S1. Patients’ excerpts exemplifying perceived
barriers and facilitators to adherence to asthma medication.
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